摘要
目的探讨GPNMB、ERK、MMP3和MMP9在肾癌原发灶和骨转移灶中的表达及意义并分析其表达的相关性。方法免疫组织化学法检测肾癌原发灶和骨转移灶中GPNMB、ERK、MMP3和MMP9的表达,并分析其结果与患者的临床指标之间的关系。结果 GPNMB在肾癌原发灶和骨转移灶中的表达量分别为3.65±1.87和5.91±3.68。GPNMB高表达组患者中发生中轴骨转移、四肢骨转移、中轴骨和四肢骨均转移的例数分别是4例、1例、3例,低表达组患者中的例数分别为10例、5例、0例(P=0.035)。ERK、MMP3和MMP9在GPNMB原发灶高表达组和低表达组中的表达量分别是7.25±2.55 vs.2.47±0.64、5.25±1.91 vs.2.33±0.49和7.00±2.98 vs.2.27±0.46(均P<0.05)。在GPNMB骨转移灶高表达组和低表达组中的表达量分别是7.45±3.67 vs.3.75±1.66、6.45±2.62 vs.3.25±0.75和7.27±3.66 vs.3.42±0.67(均P<0.05)。结论肾癌原发灶中GPNMB的表达可在一定程度上预测肾癌骨转移的范围,肾癌原发灶和骨转移灶中GPNMB的高表达与ERK、MMP3和MMP9高表达相关。
Objective To investigate the expression and significance of GPNMB,ERK,MMP3 and MMP9 in primary lesion and bone metastasis of renal cell carcinoma,and to analyze their correlation.Methods The expression of GPNMB,ERK,MMP3 and MMP9 in primary lesion and bone metastases of renal cell carcinoma were detected by immunohistochemistry.The correlation of GPNMB expression with the clinical pathological features of renal cell carcinoma patients with bone metastasis was analyzed.Results GPNMB expression in primary tumor and bone metastasis were 3.65±1.87 and 5.91±3.68.There were 4,1 and 3 cases of axial,appendicular and both axial and appendicular bone metastasis in the high GPNMB expression group,while there were 10,5 and 0 cases in low expression group,respectively(P=0.035).The expression of ERK,MMP3 and MMP9 between the high and low GPNMB expression groups in primary tumor were 7.25±2.55 vs.2.47±0.64,5.25±1.91 vs.2.33±0.49 and 7.00±2.98 vs.2.27±0.46;while they were 7.45±3.67 vs.3.75±1.66,6.45±2.62 vs.3.25±0.75 and 7.27±3.66 vs.3.42±0.67 between the high and low GPNMB expression groups in bone metastasis(all P<0.05).Conclusion The expression of GPNMB in the primary lesion of renal cell carcinoma could predict the extent of bone metastasis.The high expression of GPNMB in primary lesion and bone metastases of renal cell carcinoma is associated with high expression of ERK,MMP3 and MMP9.
作者
翟建坡
刘宁
王海
王海东
满立波
ZHAI Jianpo;LIU Ning;WANG Hai;WANG Haidong;MAN Libo(Department of Urology,Beijing Jishuitan Hospital,Beijing 100096,China)
出处
《肿瘤防治研究》
CAS
CSCD
2020年第5期367-371,共5页
Cancer Research on Prevention and Treatment
基金
北京市医院管理局“青苗”计划专项(QML20170405)
北京积水潭医院“学科新星”计划专项(XKXX201616)。